BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11898580)

  • 21. Secondary prevention of stroke: a practical guide to drug treatment.
    Koennecke HC
    CNS Drugs; 2004; 18(4):221-41. PubMed ID: 15015903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack.
    Davis SM; Donnan GA
    N Engl J Med; 2012 May; 366(20):1914-22. PubMed ID: 22591297
    [No Abstract]   [Full Text] [Related]  

  • 23. Medical therapy for secondary prevention of stroke.
    Regesta G
    Clin Exp Hypertens; 2002; 24(7-8):555-62. PubMed ID: 12450231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antithrombotic therapy in the secondary prevention of stroke].
    Mel'nikova EV; Kadinskaia MI; Gerasimenko DV; Shmonin AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12 Pt 2):23-7. PubMed ID: 21626814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelet aggregating versus anticoagulant agents in preventing early recurrent stroke among patients with atrial fibrillation.
    Adams HP
    Curr Neurol Neurosci Rep; 2001 Jan; 1(1):11-2. PubMed ID: 11898494
    [No Abstract]   [Full Text] [Related]  

  • 26. The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation.
    Golive A; May HT; Bair TL; Jacobs V; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2017 Jul; 120(1):75-82. PubMed ID: 28483209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of anticoagulants or antiplatelet aggregating drugs in the prevention of ischemic stroke.
    Adams HP
    Adv Intern Med; 1995; 40():503-31. PubMed ID: 7747656
    [No Abstract]   [Full Text] [Related]  

  • 28. Transient ischaemic attacks : new approaches to management.
    Madhavan R; Chaturvedi S
    CNS Drugs; 2003; 17(5):293-305. PubMed ID: 12665389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How good is the management of vascular risk after stroke, transient ischaemic attack or carotid endarterectomy?
    Johnson P; Rosewell M; James MA
    Cerebrovasc Dis; 2007; 23(2-3):156-61. PubMed ID: 17124397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombotic treatment in the prevention of ischemic stroke.
    Emre U; Rantanen K; Tatlisumak T
    Curr Drug Targets; 2007 Jul; 8(7):817-23. PubMed ID: 17630934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.
    ; Halkes PH; van Gijn J; Kappelle LJ; Koudstaal PJ; Algra A
    Lancet Neurol; 2007 Feb; 6(2):115-24. PubMed ID: 17239798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
    Liu F; Tantry US; Gurbel PA
    Expert Opin Pharmacother; 2015 Jun; 16(8):1149-65. PubMed ID: 25873127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack.
    Depta JP; Fowler J; Novak E; Katzan I; Bakdash S; Kottke-Marchant K; Bhatt DL
    Stroke; 2012 Sep; 43(9):2376-81. PubMed ID: 22713488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Secondary prophylaxis of stroke from a neurological perspective].
    Seidel G
    Herz; 2013 May; 38(3):251-60. PubMed ID: 23471343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
    Lalouschek W; Lang W; Müllner M;
    Stroke; 2001 Dec; 32(12):2860-6. PubMed ID: 11739988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiplatelet treatment in the secondary prevention of coronary and cerebrovascular disease: is there any place for novel agents?
    Ntalas IV; Milionis HJ; Kei AA; Kalantzi KI; Goudevenos JA
    Angiology; 2014 Jul; 65(6):473-90. PubMed ID: 23966569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke.
    Shrestha S; Coy S; Bekelis K
    Curr Pharm Des; 2017; 23(9):1377-1391. PubMed ID: 28003013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary prevention by stroke subtype: a nationwide follow-up study in 46 108 patients after acute ischaemic stroke.
    Kim D; Lee SH; Joon Kim B; Jung KH; Yu KH; Lee BC; Roh JK;
    Eur Heart J; 2013 Sep; 34(35):2760-7. PubMed ID: 23729692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.